IL216624A - Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene - Google Patents
Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) GeneInfo
- Publication number
- IL216624A IL216624A IL216624A IL21662411A IL216624A IL 216624 A IL216624 A IL 216624A IL 216624 A IL216624 A IL 216624A IL 21662411 A IL21662411 A IL 21662411A IL 216624 A IL216624 A IL 216624A
- Authority
- IL
- Israel
- Prior art keywords
- deoxymannose
- epimerase
- keto
- reductase
- glycoprotein
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 230000033581 fucosylation Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18340009P | 2009-06-02 | 2009-06-02 | |
| US34885810P | 2010-05-27 | 2010-05-27 | |
| PCT/US2010/036914 WO2010141478A1 (en) | 2009-06-02 | 2010-06-01 | Fucosylation-deficient cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL216624A0 IL216624A0 (en) | 2012-02-29 |
| IL216624A true IL216624A (en) | 2015-02-26 |
Family
ID=42338231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL216624A IL216624A (en) | 2009-06-02 | 2011-11-27 | Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US8409838B2 (enExample) |
| EP (3) | EP2808393B1 (enExample) |
| JP (4) | JP5744856B2 (enExample) |
| KR (2) | KR101641526B1 (enExample) |
| CN (1) | CN102459603B (enExample) |
| AU (1) | AU2010256753B2 (enExample) |
| BR (1) | BRPI1010035A2 (enExample) |
| CA (1) | CA2764370C (enExample) |
| DK (3) | DK3279326T3 (enExample) |
| ES (2) | ES2661074T3 (enExample) |
| HU (1) | HUE038596T2 (enExample) |
| IL (1) | IL216624A (enExample) |
| PL (3) | PL3279326T3 (enExample) |
| SG (1) | SG176251A1 (enExample) |
| TW (1) | TWI513818B (enExample) |
| WO (1) | WO2010141478A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140161782A1 (en) | 2008-06-09 | 2014-06-12 | Targazyme, Inc. | Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase |
| SG176251A1 (en) | 2009-06-02 | 2011-12-29 | Regeneron Pharma | Fucosylation-deficient cells |
| WO2012120500A2 (en) | 2011-03-06 | 2012-09-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| WO2013013013A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for producing modified glycoproteins |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2722673B1 (en) | 2012-10-17 | 2017-07-12 | Hexal AG | Improved method of mapping glycans of glycoproteins |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
| WO2015057393A1 (en) * | 2013-10-01 | 2015-04-23 | University Of Wyoming | Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production recombinant glycoproteins |
| EA035809B1 (ru) | 2014-03-11 | 2020-08-14 | Регенерон Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ |
| KR20250012733A (ko) * | 2014-05-30 | 2025-01-24 | 뉴 잉글랜드 바이오랩스, 인크 | 탈당화 시약 및 방법 |
| US20170121673A1 (en) * | 2014-07-07 | 2017-05-04 | Targazyme, Inc. | Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Use |
| CN105671109B (zh) * | 2014-11-20 | 2019-08-23 | 中国人民解放军军事医学科学院生物工程研究所 | 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| AU2016350732A1 (en) * | 2015-11-02 | 2018-04-05 | Genentech, Inc. | Methods of making fucosylated and afucosylated forms of a protein |
| WO2017120347A1 (en) * | 2016-01-06 | 2017-07-13 | Oncobiologics, Inc. | Modulation of afucosylated species in a monoclonal antibody composition |
| WO2017136433A1 (en) | 2016-02-03 | 2017-08-10 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| SG10202010156XA (en) | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| CN109195986B (zh) | 2016-04-20 | 2023-01-03 | 瑞泽恩制药公司 | 基于使用表达增强性基因座来制备抗体的组合物和方法 |
| EP3339444A1 (en) * | 2016-12-20 | 2018-06-27 | Mabxience Research, S.L. | Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans |
| KR20200135781A (ko) | 2018-03-26 | 2020-12-03 | 암젠 인크 | 세포 배양에서 생산된 항체의 총 비푸코실화 당형태 |
| CN113166728A (zh) * | 2018-08-29 | 2021-07-23 | 联合生物制药股份有限公司 | 去岩藻醣基化抗体及其制造 |
| US20220002389A1 (en) | 2018-10-29 | 2022-01-06 | Immuno-Biological Laboratories Co., Ltd. | Anti-hiv antibody and method for producing same |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| US20240043504A1 (en) | 2020-05-26 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments |
| CA3181026A1 (en) | 2020-06-03 | 2021-12-09 | Samit GANGULY | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| CN112843234B (zh) * | 2021-01-20 | 2022-09-06 | 四川大学华西第二医院 | 一种调控生物机体内gdp-甘露糖的浓度的装置 |
| CA3222409A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| US20240293566A1 (en) | 2021-06-22 | 2024-09-05 | Regeneron Pharmaceuticals, Inc. | ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOF |
| TW202321292A (zh) | 2021-07-14 | 2023-06-01 | 美商再生元醫藥公司 | 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段 |
| WO2023081434A2 (en) | 2021-11-07 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies |
| EP4486778A1 (en) | 2022-03-02 | 2025-01-08 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1006070A (en) | 1909-05-11 | 1911-10-17 | George Walter Durbrow | Method of and means for extracting micro-organisms and solids from water. |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| JP2001145488A (ja) | 1999-11-19 | 2001-05-29 | Natl Inst Of Advanced Industrial Science & Technology Meti | シロイヌナズナ由来のｇｄｐ−４−ケト−６−デオキシ−ｄ−マンノース−３，５−エピメラーゼ−４−レダクターゼ遺伝子 |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| KR100877676B1 (ko) * | 2000-10-06 | 2009-01-09 | 교와 핫꼬 기린 가부시키가이샤 | 항체 조성물을 생산하는 세포 |
| US20020150968A1 (en) | 2001-01-10 | 2002-10-17 | Wang Peng G. | Glycoconjugate and sugar nucleotide synthesis using solid supports |
| EP1392859B1 (en) | 2001-01-16 | 2006-05-10 | Regeneron Pharmaceuticals, Inc. | Isolating cells expressing secreted proteins |
| EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
| KR100585140B1 (ko) | 2004-04-26 | 2006-05-30 | 삼성전자주식회사 | 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법 |
| US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
| US20090208500A1 (en) | 2005-06-03 | 2009-08-20 | Genentech, Inc. | Method of producing antibodies with improved function |
| ME01786B (me) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimizovana antitela usmerena na cd19 |
| WO2008112092A2 (en) | 2007-03-07 | 2008-09-18 | Glycofi, Inc. | Production of glycoproteins with modified fucosylation |
| ES2522615T3 (es) | 2007-06-04 | 2014-11-17 | Regeneron Pharmaceuticals, Inc. | Regiones de expresión y estabilidad potenciadas |
| EP2311864A4 (en) | 2008-08-13 | 2013-07-31 | Kyowa Hakko Kirin Co Ltd | RECOMBINANT PROTEIN-S COMPOSITION |
| SG176251A1 (en) | 2009-06-02 | 2011-12-29 | Regeneron Pharma | Fucosylation-deficient cells |
| WO2012120500A2 (en) | 2011-03-06 | 2012-09-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
-
2010
- 2010-06-01 SG SG2011087517A patent/SG176251A1/en unknown
- 2010-06-01 HU HUE14179885A patent/HUE038596T2/hu unknown
- 2010-06-01 DK DK17192430.1T patent/DK3279326T3/da active
- 2010-06-01 BR BRPI1010035-0A patent/BRPI1010035A2/pt not_active Application Discontinuation
- 2010-06-01 KR KR1020147007025A patent/KR101641526B1/ko not_active Expired - Fee Related
- 2010-06-01 JP JP2012514045A patent/JP5744856B2/ja not_active Expired - Fee Related
- 2010-06-01 AU AU2010256753A patent/AU2010256753B2/en not_active Ceased
- 2010-06-01 DK DK14179885.0T patent/DK2808393T3/en active
- 2010-06-01 WO PCT/US2010/036914 patent/WO2010141478A1/en not_active Ceased
- 2010-06-01 TW TW099117652A patent/TWI513818B/zh not_active IP Right Cessation
- 2010-06-01 KR KR1020117031320A patent/KR101441437B1/ko not_active Expired - Fee Related
- 2010-06-01 PL PL17192430T patent/PL3279326T3/pl unknown
- 2010-06-01 CN CN2010800294912A patent/CN102459603B/zh not_active Expired - Fee Related
- 2010-06-01 ES ES14179885.0T patent/ES2661074T3/es active Active
- 2010-06-01 EP EP14179885.0A patent/EP2808393B1/en active Active
- 2010-06-01 EP EP17192430.1A patent/EP3279326B1/en active Active
- 2010-06-01 US US12/791,637 patent/US8409838B2/en active Active
- 2010-06-01 PL PL10721096T patent/PL2438171T3/pl unknown
- 2010-06-01 PL PL14179885T patent/PL2808393T3/pl unknown
- 2010-06-01 CA CA2764370A patent/CA2764370C/en active Active
- 2010-06-01 DK DK10721096.5T patent/DK2438171T3/en active
- 2010-06-01 EP EP10721096.5A patent/EP2438171B1/en active Active
- 2010-06-01 ES ES10721096.5T patent/ES2527173T3/es active Active
-
2011
- 2011-11-27 IL IL216624A patent/IL216624A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/779,952 patent/US9206455B2/en active Active
-
2014
- 2014-12-12 JP JP2014251541A patent/JP2015051021A/ja not_active Withdrawn
-
2015
- 2015-12-08 US US14/963,178 patent/US9550823B2/en active Active
-
2016
- 2016-03-07 JP JP2016043151A patent/JP6211642B2/ja not_active Expired - Fee Related
- 2016-10-14 JP JP2016202634A patent/JP2017006147A/ja active Pending
- 2016-12-14 US US15/378,670 patent/US10006070B2/en active Active
-
2018
- 2018-05-23 US US15/987,286 patent/US20190024129A1/en not_active Abandoned
-
2019
- 2019-08-30 US US16/556,334 patent/US20200080124A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,255 patent/US11560550B2/en active Active
-
2022
- 2022-12-15 US US18/066,303 patent/US12054751B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216624A (en) | Cells and Methods for Glycoprotein Preparation with Reduced Focosylation Using a Gdp-4-Keto-6-Deoxy-Mannose-3,5-Epimerase-4-Reductase (fx) Gene | |
| EP2461418B8 (en) | Battery module, and method for cooling a battery module | |
| EP2251395B8 (en) | Methods for increase gas production and load recovery | |
| IL252045B (en) | Isolated nucleic acid, expression vector and cell culture comprising the nucleic acid | |
| BR112012001351A2 (pt) | Método, célula de levedura engenheirada geneticamente, e, co-cultura de bactéria-levedura. | |
| IL216902A0 (en) | Methods for culturing stem and progentitor cells | |
| IL217026A0 (en) | Capsule, system and method for the prepartion of a beverage and a method for manufacturing such a capsule | |
| EP2477262A4 (en) | Gas diffusion layer and process for production thereof, and fuel cell | |
| EP2506505A4 (en) | Load distribution system, load distribution method, and program | |
| TWI563674B (en) | Method for making a solar battery,and solar battery | |
| EP2660345A4 (en) | Steel sheet having enhanced ductility for a molding member, molding member, and method for manufacturing same | |
| EP2415693A4 (en) | Composite tank, manufacturing method therefor, and wing | |
| EP2408021A4 (en) | Process for producing solar battery, and solar battery | |
| ZA201106415B (en) | Interface module,system and method | |
| GB0909110D0 (en) | Biometric method, system and computer program | |
| IL219600A0 (en) | Germline stem cell banking system | |
| PL2414300T3 (pl) | Sposób wytwarzania szklanego pojemnika i odpowiedni pojemnik | |
| IL217857A (en) | Method for Preparation of α3 - Hydroxy, ß3 - Methyl - α5 - Pryganan - 20 - On (Genaxulone) | |
| EP2473583A4 (en) | SYSTEM AND METHOD FOR PRODUCING BIODIESEL | |
| SG11201402586YA (en) | Mutant xylanase, manufacturing method and use therefor, and method for manufacturing saccharified lignocellulose | |
| EP2677593A4 (en) | CELL HOUSING AND STRUCTURE FOR FIXING THE CELL HOUSING | |
| EP2595225A4 (en) | METHOD FOR PRODUCING A FUEL CELL CATALYST, FUEL CELL CATALYST AND USE THEREOF | |
| ZA201107892B (en) | High-volume-manufacture fuel cell arrangement and method for production thereof | |
| EP2579373A4 (en) | OPERATING METHOD FOR FUEL CELL AND FUEL CELL SYSTEM | |
| IL218026A0 (en) | Processes for culturing prokaryotic cells, cells produced thereby and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |